Blair William & Co. IL Decreases Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Blair William & Co. IL lessened its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 8.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,047 shares of the biotechnology company’s stock after selling 569 shares during the period. Blair William & Co. IL’s holdings in Blueprint Medicines were worth $652,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Principal Financial Group Inc. lifted its stake in shares of Blueprint Medicines by 331.9% during the first quarter. Principal Financial Group Inc. now owns 62,670 shares of the biotechnology company’s stock worth $5,945,000 after purchasing an additional 48,160 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Blueprint Medicines in the first quarter valued at approximately $474,000. Vanguard Group Inc. raised its stake in shares of Blueprint Medicines by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock valued at $564,045,000 after purchasing an additional 147,827 shares during the period. Comerica Bank lifted its position in shares of Blueprint Medicines by 2,582.9% during the first quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after purchasing an additional 10,435 shares in the last quarter. Finally, Axiom Investors LLC DE acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $2,212,000.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, insider Debra Durso-Bumpus sold 3,850 shares of Blueprint Medicines stock in a transaction on Friday, July 5th. The stock was sold at an average price of $111.20, for a total transaction of $428,120.00. Following the sale, the insider now owns 43,763 shares of the company’s stock, valued at approximately $4,866,445.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the sale, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Debra Durso-Bumpus sold 3,850 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $111.20, for a total transaction of $428,120.00. Following the transaction, the insider now owns 43,763 shares in the company, valued at approximately $4,866,445.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,913 shares of company stock worth $5,352,249. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Trading Down 3.6 %

NASDAQ:BPMC opened at $87.00 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. The firm has a market capitalization of $5.51 billion, a P/E ratio of -18.09 and a beta of 0.58. Blueprint Medicines Co. has a 12-month low of $43.89 and a 12-month high of $121.90. The business has a 50 day simple moving average of $96.02 and a 200 day simple moving average of $98.98.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The business had revenue of $138.20 million for the quarter, compared to analysts’ expectations of $104.02 million. During the same quarter last year, the company earned ($2.19) EPS. The company’s revenue for the quarter was up 139.9% compared to the same quarter last year. Equities research analysts predict that Blueprint Medicines Co. will post -3.99 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on BPMC shares. Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Guggenheim boosted their price target on Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Needham & Company LLC restated a “buy” rating and set a $130.00 price objective on shares of Blueprint Medicines in a research note on Thursday, August 1st. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, June 7th. Finally, Morgan Stanley raised their price target on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research report on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.